Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134552 | 0.94 | SMN1; SMN2 (0.49) | ALKKITFLT3HDAC1ADORA2A | |
| SCHEMBL6133110 | 0.93 | SMN1; SMN2 (0.49) | ALKKITFLT3HDAC1ADORA2A | |
| SCHEMBL6134455 | 0.92 | HIF1A (0.48) | ALKHDAC1ADORA2AADORA1TNIK | |
| SCHEMBL6133384 | 0.88 | ADORA2A (0.50) | ADORA2AADORA1 | |
| SCHEMBL6133303 | 0.86 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL6133349 | 0.85 | ADORA2A (0.53) | ADORA2AADORA1 | |
| SCHEMBL6133816 | 0.85 | HDAC1 (0.52) | HDAC1ADORA2AADORA1 | |
| SCHEMBL6133433 | 0.85 | ADORA2A (0.48) | ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL6133681 | 0.85 | ALDH1A1 (0.49) | KITADORA2AADORA1TRPV4 | |
| SCHEMBL6133807 | 0.84 | SMN1; SMN2 (0.46) | HDAC1ADORA2AADORA1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | ALK 66/4885KIT 3360/4885FLT3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.